[194 Pages Report] Retinal biologics market revenue totaled US$ 19.96 Billion in 2021. The global market is expected to reach US$ 41.92 Billion by 2028, surging at a CAGR of 11.1% over the period of 2022 to 2028.
| Attribute | Details |
|---|---|
| Retinal Biologics Market Size (2022) | US$ 22.25 Billion |
| Sales Forecast (2028) | US$ 41.92 Billion |
| Global Market Growth Rate (2022 to 2028) | 11.1% CAGR |
| Share of Top 5 Players | 50% |
Retinal biologics accounted for 6.9% share of the global biologic therapeutics market in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 11.08% |
| H1, 2022 Projected | 11.14% |
| H1, 2022 Outlook | 10.94% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 20 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 14 ↓ |
According to Future Market Insights' analysis, the global retinal biologics market expects to drop by 14 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 20 BPS.
The availability of very few retinal biologics, their severe side effects, rigorous regulatory standards involved with obtaining biologics approvals, and the exorbitant cost of effective drugs and biologics are all contributing factors to the drop in BPS values.
The market will however witness a positive growth outlook over the forecast period, owed to the increasing intensive research activities for the production of novel biologics for novel disease therapeutics.
The key development in the market includes innovations in ocular drug delivery to the retina with the development of intravitreal drugs. The retinal biologics market is subject to macroeconomic and industrial factors in accordance to stringent regulatory standards and approval activities for biologics.
“Rising Burden of Retinal Diseases to Boost Overall Market Growth”
From 2013 to 2021, the global retinal biologics market registered significant gains, experiencing a CAGR worth 10.2%
Retinal biologics are bioengineered molecules that are implanted inside the eyes to heal chronic retinal diseases. Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Some of the retinal biologics used for retinal diseases are Eylea, Lucentis, Humira, Macugen, and others.
Increased frequency of retinal diseases such as age-related macular degeneration around the world is driving the market expansion. According to WHO statistics, nearly 2.2 billion individuals worldwide suffer from near or distance vision impairment. As the prevalence of vision impairment rises, the need for effective therapeutic alternatives, such as retinal biologics, is rising as well.
Retinal biologics are a new class of medications that target specific markers in the patient's body to alleviate the symptoms of a variety of systemic or ocular disorders that present in the eye.
Considering these factors, the market is projected to witness high growth over the forecast period, registering an impressive CAGR of 11.1% to reach US$ 41.92 Bn by 2028.
“Rising R&D Activities in Retinal Gene Therapies to Fuel Market Expansion”
The market will be driven by a strong focus on R&D connected with retinal gene therapies conducted by different institutes, biologics firms, and innovative product releases by prominent market participants in the form of biologics and implants. Efforts to develop a complementary therapeutic treatment will boost the market growth.
“Market Growth Complemented by Increasing Burden of Retinal Diseases”
Diabetic retinopathy has been a rising concern as the disease leads to vision loss among type I and type II adult diabetic patients. Diabetic macular edema also results from the consequences of diabetic retinopathy, which leads to the swelling of the macula. Moreover, increasing burden of other retinal diseases such as uveitis and orbital inflammation is another factor surging demand for retinal drugs and biologics.
Retinal gene therapy is a therapeutic approach wherein inherited defective genes are replaced by treatment with DNA or RNA. Retinal gene therapy is considered to be a significant approach as there occurs less contamination, and the viral vector can easily accommodate within the eyes.
“Regulatory Obstructions Likely to Hinder Demand for Retinal Biologics”
Limited availability of retinal biologics, hazardous biologic side effects, and limited access for retinal biologics and efficient treatments due to higher costs are restraining the market growth.
The market is being challenged by the side effects of retinal biologics, which include retinal tear, sickness, and eye pain. Governing authorities' strict regulatory compliances associated with biologics approval are impeding industry growth.
Principal Consultant
“Ongoing Advancements in Biologics for Retinal Treatment”
North America is expected to have a significant share in the global retinal biologics market. Continuous improvements in healthcare infrastructure, as well as an increase in the number of cases of retinal illnesses and favorable reimbursement policies, are expected to promote market expansion in the region.
Prominent presence of key manufacturers and increased healthcare spending are driving market growth in the region. Growing diabetes population is a major driver in the development of biologics for retinal treatment in North America.
“Increased Prevalence of Diabetic Macular Edema to Augment Demand for Retinal Biologics”
Diabetic retinopathy is a disease that affects people who have diabetes. Diabetic retinopathy is the major cause of new incidents of blindness in adults aged 20 to 74 years in the United States.
According to a new research study released by the Centers for Disease Control and Prevention, more than 100 million persons in the United States currently have diabetes or prediabetes.
In addition, researchers are working on innovative strategies to treat diabetic macular edema. As a result, rising R&D spending in the country as well as risk factors that contribute to disease development will have an impact on the retinal biologics market in the U.S. over the forecast period.
“Rising Efforts for Development of Retinal Drugs to Drive Market Growth.”
The market in China is expected to grow due to rapidly rising cases of uveitis, diabetic retinopathy, and macular degeneration. Diabetes is exacerbated by a shift in lifestyle and an increase in bad eating habits, as a result of these factors, the global market for retinal drugs and biologics is expected to expand significantly.
Along with increasing incidence of eye diseases, there are a growing number of research initiatives focused on retinal drugs. Furthermore, growing geriatric population, which is becoming a target patient pool for retinal biologics, will boost market growth in China.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“VEGF-A Antagonists Most Preferred as They are Largely Tolerated & Give Instant Results to Eye Disorders.”
VEGF-A antagonists are used to treat eye damage and enhance corneal wound healing. The global retinal biologics market is also expected to be fueled by the rising prevalence of other retinal illnesses such as orbital inflammation and uveitis.
VEGF-A antagonists are commonly given for the treatment of diabetic retinopathy and diabetic macular edema. In the case of non-infectious uveitis, it is seen to be the ideal alternative to typical suppressing treatments.
Many firms have focused on VEGF-A antagonists because they reduce angiogenesis. Manufacturers are investing in the development of retinal biologics in a similar field due to the widespread acceptance of VEGF-A antagonist therapy.
“Increasing Adoption of Retinal Biologics for Macular Degeneration Treatment”
Macular degeneration indication is expected to account 36.9% share of the retinal biologics market in 2022. Macular Degeneration is a vision loss condition that affects the macula.
Despite the availability of improved treatment alternatives, the global retinal biologics market is likely to benefit from the increased prevalence of macular degeneration. According to the American Macular Degeneration Foundation, the prevalence is higher than the combined rates of cataracts and glaucoma in over 10 million Americans (AMDF).
Because macular degeneration primarily affects adults aged 50 and over, the prevalence of MD continues to go up, despite improving treatment choices, as the population ages.
The COVID-19 pandemic has had a massive effect on the worldwide healthcare system, resulting in a decreased focus on retinal biologics. The COVID-19 pandemic has disrupted global care patterns and prompted broad modifications in disease management across a wide range of therapeutic disciplines. Ophthalmology was one of the first areas to be affected.
The retinal biologics industry is expected to recover soon, owing to an increase in research efforts and significant government support. The importance of treatments and disease control protocols may increase demand for retinal biologics over the coming years
Several companies are entering into licensing and collaboration agreements to expand their products into various countries across the world to cater to unmet demand. Leading market players are concentrating their efforts on research & development to discover new medications and improve treatment options.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in US$ Million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey |
| Key Market Segments Covered | Drug Class, Indication, Distribution Channel, Region |
| Key Companies Profiled | Spark Therapeutics, Inc.; F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Novartis Pharma AG; MeiraGTx Limited; Oxurion NV; Santen Pharmaceutical Co., Ltd.; Bayer AG; Bausch Health Companies Inc.; Merck & Co., Inc. |
| Pricing | Available upon Request |
Retinal Biologics Market by Drug Class:
Retinal Biologics Market by Indication:
Retinal Biologics Market by Distribution Channel:
Retinal Biologics Market by Region:
The global retinal biologics market is estimated to exhibit a CAGR of 11.1% during the forecast period (2022-2028).
Macular degeneration accounts for 36.9% share of the retinal biologics market.
The global retinal biologics market is expected to reach a valuation of US$ 41.92 Bn by 2028.
Increasing prevalence of diabetic eye diseases and significant R&D investments for developing biologics are key trends driving market growth.
Major players operating in the market include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., AbbVie Inc., and Amgen Inc.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Global Economic Outlook
3.1. Gross Domestic Indication Type by Region & Country, 2006 – 2021
3.2. Global Healthcare Market Indicators
4. Market Opportunity Analysis
4.1. Macro-Economic Factors
4.2. Opportunity Analysis
5. Market Dynamics
5.1. Drivers
5.1.1. Supply Side Drivers
5.1.2. Demand Side Drivers
5.2. Restraints
5.3. Trends
6. Key Inclusion
6.1. Key Regulations
6.2. Reimbursement Scenario
6.3. Pricing Analysis
7. North America Market Analysis 2013–2021 and Forecast 2022–2028
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
7.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
7.4.1. VEGF-An antagonist
7.4.2. TNF-α inhibitor
7.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
7.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
7.6.1. Macular Degeneration
7.6.2. Diabetic Retinopathy
7.6.3. Diabetic Macular Edema
7.6.4. Uveitis
7.6.5. Others
7.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
7.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
7.8.1. Institutional Sales
7.8.1.1. Specialty Clinics
7.8.1.2. Hospitals
7.8.2. Retail Sales
7.8.2.1. Retail Pharmacies
7.8.2.2. Mail Order Pharmacies
7.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Drug Class
7.10.3. By Indication
7.10.4. By Distributional Channel
7.11. Drivers and Restraints: Impact Analysis
7.12. Key Market Participants – Intensity Mapping
8. Latin America Market Analysis 2013–2021 and Forecast 2022–2028
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
8.3.1. Brazil
8.3.2. Mexico
8.3.3. Argentina
8.3.4. Rest of Latin America
8.4. Market Size (US$ Mn) Forecast By Country, 2022-2028
8.5. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
8.5.1. VEGF-A antagonist
8.5.2. TNF-α inhibitor
8.6. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
8.7. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
8.7.1. Macular Degeneration
8.7.2. Diabetic Retinopathy
8.7.3. Diabetic Macular Edema
8.7.4. Uveitis
8.7.5. Others
8.8. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
8.9. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
8.9.1. Institutional Sales
8.9.1.1. Specialty Clinics
8.9.1.2. Hospitals
8.9.2. Retail Sales
8.9.2.1. Retail Pharmacies
8.9.2.2. Mail Order Pharmacies
8.10. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Drug Class
8.11.3. By Indication
8.11.4. By Distributional Channel
8.12. Drivers and Restraints: Impact Analysis
8.13. Key Market Participants – Intensity Mapping
9. Western Europe Market Analysis 2013–2021 and Forecast 2022–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
9.2.1. Germany
9.2.2. U.K
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Western Europe
9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
9.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
9.4.1. VEGF-A antagonist
9.4.2. TNF-α inhibitor
9.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
9.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
9.6.1. Macular degeneration
9.6.2. Diabetic Retinopathy
9.6.3. Diabetic Macular Edema
9.6.4. Uveitis
9.6.5. Others
9.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
9.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
9.8.1. Institutional Sales
9.8.1.1. Specialty Clinics
9.8.1.2. Hospitals
9.8.2. Retail Sales
9.8.2.1. Retail Pharmacies
9.8.2.2. Mail Order Pharmacies
9.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Class
9.10.3. By Indication
9.10.4. By Distributional Channel
9.11. Drivers and Restraints: Impact Analysis
9.12. Key Market Participants – Intensity Mapping
10. Eastern Europe Market Analysis 2013–2021 and Forecast 2022–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
10.2.1. Russia
10.2.2. Poland
10.2.3. Rest of Eastern Europe
10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
10.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
10.4.1. VEGF-A antagonist
10.4.2. TNF-α inhibitor
10.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
10.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
10.6.1. Macular degeneration
10.6.2. Diabetic Retinopathy
10.6.3. Diabetic Macular Edema
10.6.4. Uveitis
10.6.5. Others
10.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
10.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021
10.8.1. Institutional Sales
10.8.1.1. Specialty Clinics
10.8.1.2. Hospitals
10.8.2. Retail Sales
10.8.2.1. Retail Pharmacies
10.8.2.2. Mail Order Pharmacies
10.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
10.10. Market Attractiveness Analysis
10.10.1. By Country
10.10.2. By Drug Class
10.10.3. By Indication
10.10.4. By Distributional Channel
10.11. Drivers and Restraints: Impact Analysis
10.12. Key Market Participants – Intensity Mapping
11. Asia Pacific Excluding Japan Market Analysis 2013–2021 and Forecast 2022–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
11.2.1. China
11.2.2. India
11.2.3. Australia and New Zealand
11.2.4. ASEAN
11.2.5. Rest of APEJ
11.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
11.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
11.4.1. VEGF-A antagonist
11.4.2. TNF-α inhibitor
11.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
11.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
11.6.1. Macular degeneration
11.6.2. Diabetic Retinopathy
11.6.3. Diabetic Macular Edema
11.6.4. Uveitis
11.6.5. Others
11.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
11.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
11.8.1. Institutional Sales
11.8.1.1. Specialty Clinics
11.8.1.2. Hospitals
11.8.2. Retail Sales
11.8.2.1. Retail Pharmacies
11.8.2.2. Mail Order Pharmacies
11.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
11.10. Market Attractiveness Analysis
11.10.1. By Country
11.10.2. By Drug Class
11.10.3. By Indication
11.10.4. By Distributional Channel
11.11. Drivers and Restraints: Impact Analysis
11.12. Key Market Participants – Intensity Mapping
12. Japan Market Analysis 2013–2021 and Forecast 2022–2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
12.2.1. VEGF-A antagonist
12.2.2. TNF-α inhibitor
12.3. Market Size (US$ Mn) and Forecast By Drug Class, 2022-2028
12.4. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
12.4.1. Macular degeneration
12.4.2. Diabetic Retinopathy
12.4.3. Diabetic Macular Edema
12.4.4. Uveitis
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast By Indication, 2022-2028
12.6. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021
12.6.1. Institutional Sales
12.6.1.1. Specialty Clinics
12.6.1.2. Hospitals
12.6.2. Retail Sales
12.6.2.1. Retail Pharmacies
12.6.2.2. Mail Order Pharmacies
12.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Indication
12.8.3. By Distributional Channel
12.9. Drivers and Restraints: Impact Analysis
12.10. Key Market Participants – Intensity Mapping
13. Middle East and Africa Market Analysis 2013–2021 and Forecast 2022–2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Rest of Middle East and Africa
13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
13.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
13.4.1. VEGF-A antagonist
13.4.2. TNF-α inhibitor
13.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
13.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
13.6.1. Macular degeneration
13.6.2. Diabetic Retinopathy
13.6.3. Diabetic Macular Edema
13.6.4. Uveitis
13.6.5. Others
13.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
13.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021
13.8.1. Institutional Sales
13.8.1.1. Specialty Clinics
13.8.1.2. Hospitals
13.8.2. Retail Sales
13.8.2.1. Retail Pharmacies
13.8.2.2. Mail Order Pharmacies
13.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
13.10. Market Attractiveness Analysis
13.10.1. By Country
13.10.2. By Drug Class
13.10.3. By Indication
13.10.4. By Distributional Channel
13.11. Drivers and Restraints: Impact Analysis
13.12. Key Market Participants – Intensity Mapping
14. Forecast Factors: Relevance and Impact
15. Forecast Assumptions
16. Competition Analysis
16.1. Competition Dashboard
16.2. Competitors Deep Dive
16.2.1. Spark Therapeutics Inc.
16.2.1.1. Overview
16.2.1.2. Key Financials
16.2.1.3. SWOT Analysis
16.2.1.4. Key Developments
16.2.1.5. Key Strategy
16.2.2. F. Hoffmann-La Roche Ltd
16.2.2.1. Overview
16.2.2.2. Key Financials
16.2.2.3. SWOT Analysis
16.2.2.4. Key Developments
16.2.2.5. Key Strategy
16.2.3. Regeneron Pharmaceuticals, Inc.
16.2.3.1. Overview
16.2.3.2. Key Financials
16.2.3.3. SWOT Analysis
16.2.3.4. Key Developments
16.2.3.5. Key Strategy
16.2.4. AbbVie Inc
16.2.4.1. Overview
16.2.4.2. Key Financials
16.2.4.3. SWOT Analysis
16.2.4.4. Key Developments
16.2.4.5. Key Strategy
16.2.5. Johnson & Johnson Services, Inc
16.2.5.1. Overview
16.2.5.2. Key Financials
16.2.5.3. SWOT Analysis
16.2.5.4. Key Developments
16.2.5.5. Key Strategy
16.2.6. Amgen Inc.
16.2.6.1. Overview
16.2.6.2. Key Financials
16.2.6.3. SWOT Analysis
16.2.6.4. Key Developments
16.2.6.5. Key Strategy
17. Global Market Analysis 2013–2021 and Forecast 2022–2028 by Region
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Mn) Analysis by Region
17.2.1. North America
17.2.2. Latin America
17.2.3. Western Europe
17.2.4. Eastern Europe
17.2.5. Asia Pacific Excluding Japan
17.2.6. Japan
17.2.7. Middle East and Africa
17.3. Market Size (US$ Mn) Forecast By Region
17.4. Market Attractiveness Analysis by Region
18. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
18.1. Introduction/Key Finding
18.2. Historical Market Size (US$ Mn) Analysis by Drug Class, 2013-2021
18.2.1. VEGF-A antagonist
18.2.2. TNF-α inhibitor
18.3. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
18.4. Market Attractiveness Analysis by Drug Class
19. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Indication
19.1. Introduction/Key Finding
19.2. Historical Market Size (US$ Mn) Analysis by Indication, 2013-2021
19.2.1. Macular degeneration
19.2.2. Diabetic Retinopathy
19.2.3. Diabetic Macular Edema
19.2.4. Uveitis
19.2.5. Others
19.3. Market Size (US$ Mn) Forecast By Indication, 2022-2028
19.4. Market Attractiveness Analysis by Indication
20. Global Market Analysis 2013–2021 and Forecast 2022–2028, By Distributional Channel
20.1. Introduction/Key Finding
20.2. Historical Market Size (US$ Mn) Analysis by Distributional Channel, 2013-2021
20.2.1. Institutional Sales
20.2.1.1. Specialty Clinics
20.2.1.2. Hospitals
20.2.2. Retail Sales
20.2.2.1. Retail Pharmacies
20.2.2.2. Mail Order Pharmacies
20.3. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
20.4. Market Attractiveness Analysis by Distributional Channel
21. Global Market Analysis 2013–2021 and Forecast 2022–2028
21.1. Global Market Value Analysis (US$ Mn)
21.2. Absolute $ Opportunity
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Retinal Biologics Market
